Section on Growth and Obesity, Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-1103, USA.
Int J Obes (Lond). 2013 Jan;37(1):1-15. doi: 10.1038/ijo.2012.144. Epub 2012 Aug 28.
Pediatric obesity is a serious medical condition associated with significant comorbidities during childhood and adulthood. Lifestyle modifications are essential for treating children with obesity, yet many have insufficient response to improve health with behavioral approaches alone. This review summarizes the relatively sparse data on pharmacotherapy for pediatric obesity and presents information on obesity medications in development. Most previously studied medications demonstrated, at best, modest effects on body weight and obesity-related conditions. It is to be hoped that the future will bring new drugs targeting specific obesity phenotypes that will allow clinicians to use etiology-specific, and therefore more effective, anti-obesity therapies.
儿科肥胖症是一种严重的医学病症，与儿童期和成年期的多种并发症相关。生活方式的改变对于治疗肥胖儿童至关重要，但许多儿童仅通过行为方法改善健康的反应不足。本综述总结了儿科肥胖症药物治疗的相对较少的数据，并介绍了正在开发中的肥胖症药物信息。大多数先前研究的药物最多只能对体重和肥胖相关疾病产生适度的影响。人们希望未来能开发出针对特定肥胖表型的新药，使临床医生能够使用病因特异性、因此更有效的抗肥胖疗法。
